ZOLL, ALNY, INCY, - CRWESelect.com Stock Report! ZOLL Medical Corp., Alnylam Pharmaceuticals, Incyte Corporation (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) November 16, 2011 -- To view video, and read the full article visit URL http://crweselect.com/27377/stock-alerts/zoll-alny-incy-crweselectcom-stock-report-zoll-medical-corp-alnylam-pharmaceuticals-incyte-corporation-video-included-inside/

ZOLL Medical Corp. (NASDAQ:ZOLL)

ZOLL announced today that fiscal 2011 revenues were $523.7 million, compared to fiscal 2010 revenues of $444.0 million, an increase of 18%. Revenue results reflected a positive foreign exchange impact of approximately $6 million. Net income for the year grew 65% to $31.3 million, compared to $18.9 million in the prior year. Gross margins improved to 57% on the year, compared to 54% in the prior year. Diluted earnings per share grew 60% to $1.39, compared to $0.87 in the prior year. Backlog at the end of the year was approximately $30 million, as compared to $14 million at the news sssdfsend of the prior fiscal year. The Company ended the year with approximately $75 million in cash and short-term investments and generated approximately $45 million in cash from operations during the year.

Furthermore, ZOLL announced today that its Board of Directors has authorized the repurchase of up to $50 million of the Company's shares of common stock.

ZOLL develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

For more information about ZOLL please visit http://www.zoll.com/

****

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

ALNY announced today that Alnylam has granted Sylentis a non-exclusive option for a new target-specific InterfeRx™ license. This license would enable the discovery, development, and commercialization of a synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma. Sylentis’ program is currently in a Phase I/II clinical trial. Upon Sylentis’ exercise of this option, Alnylam would receive upfront and milestone payments, as well as royalties on sales of products covered by the licensing agreement. Additional financial details were not disclosed. Sylentis is a wholly owned subsidiary of Grupo Zeltia.

ALNY is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia. As part of its “Alnylam 5x15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015. ALNY has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington’s disease. The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, ALNY and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™ platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts.

For more information about ALNY please visit http://www.alnylam.com/

****

Incyte Corporation (NASDAQ:INCY)

INCY announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi™ (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Patients with intermediate and high-risk MF represent 80 to 90 percent of MF patients. Jakafi (JAK-ah-fye) is the first and only product to be approved by the FDA for MF, and the first in a new class of drugs, known as JAK inhibitors, to be approved for any indication. Jakafi is an oral JAK1 and JAK2 inhibitor.

INCY is a Wilmington, Delaware-based biopharmaceutical company focused on developing and commercializing proprietary small molecule drugs for oncology and inflammation.

For more information about INCY please visit http://www.incyte.com/

To read the full article visit URL http://crweselect.com/27377/stock-alerts/zoll-alny-incy-crweselectcom-stock-report-zoll-medical-corp-alnylam-pharmaceuticals-incyte-corporation-video-included-inside/

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

ZOLLcrweselect1116
ALNYcrweselect1116
INCYcrweselect1116

alny     Alnylam Pharmaceuticals     INCY     Incyte Corporation     NASDAQ ALNY     NASDAQ ZOLL     zoll     ZOLL Medical Corp.